About Achieve life sciences
Achieve Life Sciences: Revolutionizing Smoking Cessation
Smoking is a global health epidemic that has been plaguing the world for decades. Despite numerous efforts to curb smoking, it remains one of the leading causes of preventable deaths worldwide. Current smoking treatments have failed to make a significant impact on reducing smoking rates and helping smokers quit. However, Achieve Life Sciences is determined to change that by revolutionizing smoking cessation.
Achieve Life Sciences is a biopharmaceutical company dedicated to developing innovative therapies for nicotine addiction and other central nervous system disorders. The company was founded in 2015 with the mission of ending the global smoking health epidemic by providing effective and safe treatments for smokers who want to quit.
The company's flagship product, Cytisinicline (also known as cytisine), is a plant-based alkaloid that has been used as an aid for smoking cessation in Eastern Europe for over 50 years. Achieve Life Sciences acquired exclusive rights to develop and commercialize cytisine in North America under the brand name "Tabex." The drug has shown promising results in clinical trials, demonstrating higher efficacy rates than current standard-of-care treatments such as nicotine replacement therapy (NRT) and varenicline (Chantix).
Cytisinicline works by binding to nicotinic acetylcholine receptors in the brain, which are responsible for nicotine addiction. By blocking these receptors' activity, cytisine reduces cravings and withdrawal symptoms associated with quitting smoking. Unlike NRT or Chantix, which are expensive and require long-term use, cytisine is affordable and only requires a short course of treatment.
Achieve Life Sciences' commitment to innovation doesn't stop at cytisine; they are also exploring other potential therapies for nicotine addiction using cutting-edge technologies such as gene editing and RNA interference (RNAi). These approaches aim to target specific genes or proteins involved in nicotine dependence, providing a more personalized and effective treatment for smokers.
Achieve Life Sciences' dedication to ending the smoking epidemic goes beyond developing new therapies. The company is also actively involved in public health initiatives, partnering with organizations such as the American Lung Association and the World Health Organization to raise awareness about smoking cessation and provide resources for smokers who want to quit.
In conclusion, Achieve Life Sciences is a biopharmaceutical company that is revolutionizing smoking cessation by developing innovative therapies for nicotine addiction. Their flagship product, cytisine, has shown promising results in clinical trials and has the potential to become a game-changer in the field of smoking cessation. With their commitment to innovation and public health initiatives, Achieve Life Sciences is poised to make a significant impact on reducing smoking rates worldwide.
achievelifesciences.com
